Clinical trials: Retinal Vein Occlusion (RVO)
Macular Degeneration, Diabetic Retinopathy
Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia
Prospective comparative clinical study. One hundred eyes of 50 patients were included. All patients received bilateral same-day intravitreal injections, with Iheezo administered to only one randomly selected eye and standard…
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion (RVO)
- Trial name
- NCT07779356
- Testing
- Iheezo, Lidocaine pledget
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Retina Consultants of Delmarva
Retinal Vein Occlusion
Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO
Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
- Trial name
- NCT02387788
- Testing
- AKB-9778
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Aerpio Therapeutics
Retinal Vein Occlusion
Combined Triple Procedure in Retinal Vein Occlusion (RVO)
The aim of this pilot study was to investigate the effects of an intravitreal combination therapy using triamcinolone and bevacizumab in patients with retinal vein occlusion (RVO).
- Trial name
- NCT00805064
- Testing
- triamcinolone and bevacizumab
- Volunteers
- 40 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients
Generally, DM is caused by insufficient insulin secretion in the body; however, the other biological mechanisms remain unclear. Long-term illness in patients with DM damages various organs in the body, such as the eyes, kidneys…
- Conditions
- Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation
- Trial name
- NCT06879301
- Testing
- Intravitreal injection of aflibercept 8 mg
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tanta University
Diabetic Retinopathy, Age Related Macular Degeneration
AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma
The purpose of this multi-center study is to evaluate the extent to which AI-assisted fundus image interpretation improves the diagnostic performance of ophthalmologists.
- Conditions
- Diabetic Retinopathy, Age Related Macular Degeneration, Retinal Vein Occlusion, Glaucoma
- Trial name
- NCT07318428
- Testing
- VUNO Med-Fundus AI
- Where
- 5 sites in South Korea
- Volunteers
- 10 people
- Sponsor
- Inje University
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.
- Trial name
- SAPPHIRE (NCT02980874)
- Testing
- suprachoroidal CLS-TA, IVT aflibercept
- Where
- 110 sites in United States, Australia and 14 more
- Volunteers
- 460 people
- Sponsor
- Clearside Biomedical, Inc.
Retinal Vein Occlusion (RVO), Macular Edema
Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF
To determine if Ozurdex implant can offer an effective treatment for macular edema associated with retinal vein occlusion when treatment with intravitreal Avastin, Lucentis, or Eylea have not demonstrated a significant response.
- Trial name
- NCT01946399
- Testing
- Ozurdex implant
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Retina Research Institute, LLC
Retinal Vein Occlusion, Macula Edema
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.
- Trial name
- NCT03093701
- Testing
- TLC399 (ProDex)
- Where
- 20 sites in United States
- Volunteers
- 31 people
- Sponsor
- Taiwan Liposome Company
Central Retinal Vein Occlusion With Macular Edema
Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas
The purpose of this study is to determine if additional panretinal photocoagulation of ischemic areas following retinal vein occlusion (RVO) may reduce the rate of recurrence and allow longer treatment intervals in anti-Vascular…
- Trial name
- PEARL (NCT02522897)
- Testing
- Ranibizumab, Laser
- Volunteers
- 60 people
- Sponsor
- PD. Dr. med. Armin Wolf
Retinal Vasculitis
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice.
- Trial name
- NCT07105228
- Testing
- aflibercept 2mg
- Where
- United States
- Volunteers
- 290,000 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Edema, Central Retinal Vein Occlusion
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
CRVO occurs when the vessels in the back of the eye become blocked. This creates a dangerous condition because the vessels are weak and prone to leakage. This results in the development of macular edema.
- Trial name
- ORION (NCT01827722)
- Testing
- Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN
- Where
- 5 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Valley Retina Institute
Retinal Vein Occlusion
A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut Microbiota
The goal of this clinical trial is to evaluate the synergistic efficacy and safety of the Tongluo Huayu Formula combined with conventional Western medical treatment for RVO, thereby providing high-quality evidence to support its…
- Trial name
- NCT07718503
- Testing
- Conbercept Ophthalmic Injection, Tongluo Huayu Formula, Laser Photocoagulation
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Retinal Vein Occlusion
Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the…
- Trial name
- NCT01580020
- Testing
- RFB002, Dexamethasone
- Where
- 37 sites in Germany
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Wet Age-related Macular Degeneration, Retinal Vein Occlusion
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
- Conditions
- Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT03790852
- Testing
- KSI-301
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Kodiak Sciences Inc
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO…
- Trial name
- TOPAZ (NCT03203447)
- Testing
- suprachoroidal CLS-TA, Lucentis or Avastin
- Where
- 92 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- Clearside Biomedical, Inc.
Macular Edema, Diabetic Macular Edema
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Trial name
- NCT02867735
- Testing
- LKA651
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion, Posterior Vitreous Detachment
Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations
This is a study of subjects with retinal vein occlusion (RVO) specifically looking at the difference in outcomes between patients with posterior vitreous detachment (PVD) and those without PVD.
- Trial name
- PADDLE (NCT00831350)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Barnes Retina Institute
Retinal Vein Occlusion
NIR Fluorescence Molecular Imaging of ANXV-800CW in RVO Patients
The primary objective is safety, tolerability and feasibility of systemic intravenous injection of ANXV-800CW in patients with RVO in three dosing-cohorts in a phase I safety study.
- Trial name
- SIGHT (NCT05133791)
- Testing
- Annexin A5
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- University Medical Center Groningen
Retinal Vein Occlusion, Macular Edema
Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits.
- Trial name
- NCT01411696
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- United States
- Volunteers
- 289 people
- Sponsor
- Allergan
Macular Edema Caused by Retinal Vein Occlusion
Dexamethasone-implant for the Treatment of RVO
To evaluate the efficacy and safety of a dexamethasone-implant alone or in combination with bevacizumab. 64 eyes are prospectively investigated.
- Trial name
- NCT01767545
- Testing
- Dexamethasone implant, Bevacizumab
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- Ludwig-Maximilians - University of Munich